

Parakkal Deepak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577375/publications.pdf>

Version: 2024-02-01

174
papers

3,460
citations

236612

25
h-index

168136

53
g-index

178
all docs

178
docs citations

178
times ranked

6946
citing authors

#	ARTICLE	IF	CITATIONS
1	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
2	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. <i>Annals of Internal Medicine</i> , 2021, 174, 1572-1585.	2.0	273
3	T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF- α) Inhibitors: Results of the REFURBISH Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 99-105.	0.2	193
4	Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 102927.	2.5	132
5	<i>Debaryomyces</i> is enriched in Crohn's disease intestinal tissue and impairs healing in mice. <i>Science</i> , 2021, 371, 1154-1159.	6.0	126
6	Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 997-1006.	0.2	111
7	Hepatosplenic T-cell lymphoma in patients receiving TNF- α inhibitor therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1150-1156.	0.8	100
8	Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 388-396.	1.9	81
9	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1592-1601.e3.	2.4	69
10	The Metoclopramide Black Box Warning for Tardive Dyskinesia: Effect on Clinical Practice, Adverse Event Reporting, and Prescription Drug Lawsuits. <i>American Journal of Gastroenterology</i> , 2013, 108, 866-872.	0.2	68
11	Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 767-774.	0.9	60
12	Melanoma and non-Melanoma Skin Cancer in Inflammatory Bowel Disease Patients following Tumor Necrosis Factor- α Inhibitor Monotherapy and in Combination with Thiopurines: Analysis of the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 267-271.	0.5	52
13	Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1569-1576.	0.9	50
14	Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 603-626.	1.0	47
15	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1005-1012.	0.5	39
16	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD's Disease Outcome and Response to Therapy. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1431-1442.	0.6	39
17	Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3685-3698.	2.0	38
18	Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2280-2288.	0.9	37

#	ARTICLE	IF	CITATIONS
19	Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1035-1043.	1.9	35
20	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 447-470.	0.6	34
21	Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome. <i>Osteoporosis International</i> , 2013, 24, 1169-1175.	1.3	33
22	Radiographical evaluation of ulcerative colitis. <i>Gastroenterology Report</i> , 2014, 2, 169-177.	0.6	33
23	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
24	Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. <i>Clinical and Experimental Gastroenterology</i> , 2013, 6, 43.	1.0	30
25	De-novo Inflammatory Bowel Disease After Bariatric Surgery: A Large Case Series. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 452-457.	0.6	29
26	Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 393-398.	0.6	28
27	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. <i>Crohn's & Colitis 360</i> , 2022, 4, otac002.	0.5	28
28	Relationship Between Mesenteric Abnormalities on Computed Tomography and Malignancy. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 409-414.	1.1	27
29	Bariatric Surgery Is Acceptably Safe in Obese Inflammatory Bowel Disease Patients: Analysis of the Nationwide Inpatient Sample. <i>Obesity Surgery</i> , 2018, 28, 1007-1014.	1.1	27
30	Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021, 161, 394-399.	0.6	27
31	Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 182-188.	0.6	23
32	Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 455-464.	0.6	23
33	Infectious complications of TNF- α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2013, 22, 269-76.	0.5	23
34	Diffusion-weighted MRI in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 433-443.	3.7	21
35	Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e87-e88.	0.9	21
36	Renal risks of sodium phosphate tablets for colonoscopy preparation: a review of adverse drug reactions reported to the US Food and Drug Administration. <i>Colorectal Disease</i> , 2011, 13, e270-e275.	0.7	20

#	ARTICLE	IF	CITATIONS
37	Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2207-2209.e3.	2.4	20
38	Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 973-980.	0.6	19
39	Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2816-2818.	2.4	19
40	Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1089-1097.	0.9	19
41	Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3557-3562.	1.1	18
42	Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. <i>Abdominal Radiology</i> , 2017, 42, 1068-1086.	1.0	17
43	Volvulus of the ileal pouch-anal anastomosis: a meta-narrative systematic review of frequency, diagnosis, and treatment outcomes. <i>Gastroenterology Report</i> , 2019, 7, 403-410.	0.6	17
44	Lubiprostone induced ischemic colitis. <i>World Journal of Gastroenterology</i> , 2013, 19, 299.	1.4	17
45	Do Gastroenterologists Adhere to Diagnostic and Treatment Guidelines for Celiac Disease?. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, e12-e20.	1.1	16
46	Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1815-1825.	0.9	16
47	Ischemic Colitis with Type I Interferons Used in the Treatment of Hepatitis C and Multiple Sclerosis: An Evaluation from the Food and Drug Administration Adverse Event Reporting System and Review of the Literature. <i>Annals of Pharmacotherapy</i> , 2013, 47, 537-542.	0.9	15
48	Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. <i>Rheumatology International</i> , 2015, 35, 661-668.	1.5	15
49	Ischaemic Colitis in Rheumatoid Arthritis Patients Receiving Tumour Necrosis Factor- α Inhibitors: An Analysis of Reports to the US FDA Adverse Event Reporting System. <i>Drug Safety</i> , 2013, 36, 329-334.	1.4	14
50	Novel Imaging Approaches in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 248-260.	0.9	13
51	P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S274-S275.	0.6	13
52	Effect of Tumor Necrosis Factor- α Inhibitors on Drug-Induced Pancreatitis in Inflammatory Bowel Disease. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1282-1287.	0.9	11
53	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1917-1925.	0.9	11
54	Ischemic colitis masquerading as colonic tumor: Case report with review of literature. <i>World Journal of Gastroenterology</i> , 2011, 17, 5324.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 884-885.	3.7	11
56	Diarrhea. <i>Disease-a-Month</i> , 2011, 57, 490-510.	0.4	10
57	Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. <i>British Journal of Radiology</i> , 2019, 92, 20180930.	1.0	10
58	Multiphase Computed Tomographic Enterography: Diagnostic Yield and Efficacy in Patients With Suspected Small Bowel Bleeding. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 438-447.	1.2	10
59	Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1698-1702.	0.9	10
60	Calcium Phosphate Nephropathy From Colonoscopy Preparations: Effect of Body Weight. <i>American Journal of Gastroenterology</i> , 2010, 105, 705.	0.2	9
61	Update on the Medical Management of Crohn's Disease. <i>Current Gastroenterology Reports</i> , 2015, 17, 41.	1.1	8
62	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's & Colitis</i> 360, 2020, 2, otaa039.	0.5	8
63	Constipation. <i>Disease-a-Month</i> , 2011, 57, 511-517.	0.4	7
64	Multidisciplinary management of perianal Crohn's disease. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 295-305.	1.0	7
65	Management of refractory inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 347-357.	1.0	6
66	Transmural Healing and MRI Remission. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E44-E45.	0.9	5
67	796 " Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study. <i>Gastroenterology</i> , 2019, 156, S-168-S-169.	0.6	5
68	Reactogenicity of the Messenger RNA SARS-CoV-2 Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease. <i>Arthritis Care and Research</i> , 2022, 74, 1953-1960.	1.5	5
69	Esophageal Small Cell Carcinoma with Synchronous Renal Cell Carcinoma: A Case Report with Review of the Literature. <i>Case Reports in Gastroenterology</i> , 2011, 5, 196-200.	0.3	4
70	S0897 Efficacy and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2020, 115, S461-S462.	0.2	4
71	Postprandial Chylomicron Output and Transport Through Intestinal Lymphatics Are Not Impaired in Active Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 1955-1957.e2.	0.6	4
72	Effect of Comorbid Celiac Disease on Hospitalized Patients with Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, S519.	0.2	4

#	ARTICLE	IF	CITATIONS
73	Evaluation of Nonalcoholic Fatty Liver Disease in Pediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 574-578.	0.9	4
74	Use of Polyethylene Glycol-based Colonoscopy Preparations Before Rectal Argon Plasma Coagulation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 803-804.	1.1	3
75	Simulated Comparison of Topical and Oral Formulations of 5-Aminosalicylate for the Treatment of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 301-308.	0.9	3
76	797 "Real-World Safety of Tofacitinib in Inflammatory Bowel Diseases: A Multi-Center Study. <i>Gastroenterology</i> , 2019, 156, S-169.	0.6	3
77	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3563-3569.	1.1	3
78	MRE Evaluation of Intestinal Inflammation. <i>Topics in Magnetic Resonance Imaging</i> , 2021, 30, 13-22.	0.7	3
79	Su450 EFFECTIVENESS AND SAFETY OF COMBINING BIOLOGICS AND/OR SMALL MOLECULES IN INFLAMMATORY BOWEL DISEASES: SYSTEMATIC REVIEW WITH META-ANALYSIS. <i>Gastroenterology</i> , 2021, 160, S-696.	0.6	3
80	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	3
81	An Analysis of Hospital Charges and Length of Stay in Patients with Eosinophilic Esophagitis Admitted for Foreign Body in the Esophagus. <i>American Journal of Gastroenterology</i> , 2013, 108, S12-S13.	0.2	2
82	Mucinous Small Bowel Adenocarcinoma Mimicking Change to Internal Penetrating Phenotype in Well-controlled Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 1732-1733.	0.2	2
83	Improving Vaccination Adherence in Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, e35.	0.6	2
84	Predicting Risk of Surgery in Patients With Small Bowel Crohn's Disease Strictures Using Computed Tomography and Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2022, , .	0.9	2
85	Tools for the Diagnosis and Management of Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 213-239.	1.0	2
86	Other Effects on the Colon. <i>Disease-a-Month</i> , 2011, 57, 518-523.	0.4	1
87	Risk of Myeloid Neoplasms in Inflammatory Bowel Disease Patients Is Linked to Exposure to Thiopurines and Not With Tumor Necrosis Factor-alpha Inhibitors. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1857-1858.	2.4	1
88	Sa1927 Natural History of Isolated Terminal Ileitis in Patients Without an Existing Diagnosis of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S406.	0.6	1
89	628 Natural History of Radiological Transmural Healing in Small Bowel Crohn's Disease Patients Undergoing Serial Enterography. <i>Gastroenterology</i> , 2016, 150, S130-S131.	0.6	1
90	Sa1805 - Outcomes after Joint Replacement Surgery in Patients with Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, S-401-S-402.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Tu1828 “Enhancing Utilization of Therapeutic Drug Monitoring in Inflammatory Bowel Disease Correlates with Improved Outcomes. <i>Gastroenterology</i> , 2019, 156, S-1140-S-1141.	0.6	1
92	784 “A Population-Based Analysis of Obesity, Metabolic Syndrome, and Cardiovascular Outcomes Among Patients With Inflammatory Bowel Disease in the National Health and Nutrition Examination Survey 2009-2010. <i>American Journal of Gastroenterology</i> , 2019, 114, S454-S454.	0.2	1
93	Tu1899 REAL-WORLD EFFECTIVENESS AND SAFETY OF TOFACITINIB IN CROHN'S DISEASE: A MULTI-CENTER STUDY. <i>Gastroenterology</i> , 2020, 158, S-1211.	0.6	1
94	Pouchitis: Bile Acid Deficiency Links Inflammation to Dysbiosis. <i>Gastroenterology</i> , 2020, 159, 1615-1616.	0.6	1
95	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis “one more arrow in the quiver of non-invasive diagnostics. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 401-402.	1.9	1
96	Reply to the Letter to the Editor: Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn’s Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e46-e46.	0.9	1
97	Safety and Effectiveness of Combining Biologics and Small Molecules in IBD: Systematic Review With Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
98	Inflammatory Bowel Disease, Celiac Disease, and Primary Sclerosing Cholangitis: Is There a Link?. <i>Gastroenterology</i> , 2021, 160, 2207.	0.6	1
99	388 HIGHER VISCERAL ADIPOSE TISSUE IS ASSOCIATED WITH LOWER RATES OF STEROID-FREE DEEP AND ENDOSCOPIC REMISSION IN PATIENTS STARTING BIOLOGIC THERAPY FOR INFLAMMATORY BOWEL DISEASES: RESULTS FROM THE CONSTELLATION STUDY. <i>Gastroenterology</i> , 2021, 160, S-79.	0.6	1
100	Comorbidity with Depression Is Associated with Increased Length of Stay and Higher Hospitalization Charges in Patients with Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, S519-S520.	0.2	1
101	Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program. <i>American Journal of Gastroenterology</i> , 2019, 114, 1017-1019.	0.2	1
102	S933 “Risk Factors for Cardiovascular Diseases in Participants With Inflammatory Bowel Diseases: Analysis of the United Kingdom Biobank. <i>American Journal of Gastroenterology</i> , 2021, 116, S443-S443.	0.2	1
103	Lower body weight and female gender: Hyperphosphatemia risk factors after sodium phosphate preparations. <i>World Journal of Gastroenterology</i> , 2011, 17, 2681.	1.4	1
104	Clinical Characteristics and Natural History of Crohn’s Disease Patients With Endoscopic Skipping of Distal Terminal Ileum on Ileoscopy. <i>American Journal of Gastroenterology</i> , 2014, 109, S495-S496.	0.2	1
105	783 “Nonalcoholic Fatty Liver Disease in a South Asian Crohn's Disease Population: External Validation of the St. Louis Steatosis Index. <i>American Journal of Gastroenterology</i> , 2019, 114, S453-S454.	0.2	1
106	Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials “is it ready for prime time yet?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 946-947.	1.9	1
107	Method for the Current Review. <i>Disease-a-Month</i> , 2011, 57, 456.	0.4	0
108	Duodenal diverticulitis: a rare cause of abnormal liver function tests. <i>Endoscopy</i> , 2012, 44, E252-E253.	1.0	0

#	ARTICLE	IF	CITATIONS
109	The Role of Gender in the Occurrence of Comorbidities in Patients with Irritable Bowel Syndrome (IBS): Analysis of the Nationwide Inpatient Sample (NIS) 2008: Presidential Poster. American Journal of Gastroenterology, 2012, 107, S705-S706.	0.2	0
110	Infection Rates with Infliximab in Inflammatory Bowel Disease Compared to Rheumatologic Diseases: A Single Center Experience. American Journal of Gastroenterology, 2012, 107, S662.	0.2	0
111	Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System. European Journal of Clinical Pharmacology, 2013, 69, 1041-1042.	0.8	0
112	Radiological and Clinical Parameters in Crohn's Disease Patients as Predictors of Response to Medical Therapy. American Journal of Gastroenterology, 2015, 110, S807-S808.	0.2	0
113	P-113 Body Fat and Skeletal Muscle Composition Differs in Crohn's Disease Patients Depending on Radiological Response to Medical Therapy. Inflammatory Bowel Diseases, 2016, 22, S45.	0.9	0
114	Tu1936 Natural History of Radiological Transmural Response Identified on Serial Enterography in Small Bowel Crohn's Disease Patients. Gastroenterology, 2016, 150, S982-S983.	0.6	0
115	Genome-Wide Search Identified Genetic Variants that can Predict TNF Antagonist Responsiveness in Inflammatory Bowel Disease Patients. Gastroenterology, 2017, 152, S78-S79.	0.6	0
116	Bariatric Surgery is Safe in Obese Inflammatory Bowel Disease Patients. Gastroenterology, 2017, 152, S136.	0.6	0
117	De-Novo Inflammatory Bowel Disease after Bariatric Surgery: A Novel Association. Gastroenterology, 2017, 152, S366-S367.	0.6	0
118	Impact of Bariatric Surgery on the Natural History of Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S367.	0.6	0
119	Genetic Risk Burden Affects Inflammatory Bowel Disease Perianal Behavior and Response to TNF Antagonists. Gastroenterology, 2017, 152, S982-S983.	0.6	0
120	Natural History and Phenotype of Inflammatory Bowel Disease with Co-Existent Celiac Disease. Gastroenterology, 2017, 152, S378.	0.6	0
121	Vitamin D Deficiency Correlates With Primary Sclerosing Cholangitis Disease Severity in Patients With Coexistent Ulcerative Colitis. American Journal of Gastroenterology, 2017, 112, S514-S515.	0.2	0
122	P165 UTILIZATION OF REACTIVE DRUG LEVEL MONITORING IN INFLAMMATORY BOWEL DISEASE. Gastroenterology, 2018, 154, S88.	0.6	0
123	Role of Abdominal Imaging in the Diagnosis of IBD Strictures, Fistulas, and Postoperative Complications. , 2018, , 79-95.		0
124	Sa1988 - Crohn's Disease Patients have an Increased Risk of Nonalcoholic Fatty Liver Disease: A Case-Control Study using MRI Proton Density Fat Fraction Mapping. Gastroenterology, 2018, 154, S-438.	0.6	0
125	160 - Anti-TNF Inhibitors are not Associated with Increased Risk of Infection after Joint Replacement Surgery. Gastroenterology, 2018, 154, S-44-S-45.	0.6	0
126	Mo1900 - Vedolizumab for the Treatment of Pouchitis. Gastroenterology, 2018, 154, S-844-S-845.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Mo1474 " Low Vitamin D Correlates with Primary Sclerosing Cholangitis Disease Severity in Patients with Coexistent Ulcerative Colitis. Gastroenterology, 2019, 156, S-1319.	0.6	0
128	Sa1854 " Impact of Bariatric Surgery on the Long-Term Clinical Course of Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, S-429.	0.6	0
129	Mo1888 " Improvement in Radiographic Small Bowel Inflammation and Starting an Anti-Integrin Leads to Worsening Hepatic Steatosis in Crohn's Disease. Gastroenterology, 2019, 156, S-875.	0.6	0
130	Sa1838 " Nonalcoholic Fatty Liver Disease with Advanced Fibrosis is Associated with Increased Risk of Rescue Corticosteroid Use, Hospitalizations and Surgeries in Crohn's Disease. Gastroenterology, 2019, 156, S-422-S-423.	0.6	0
131	660 " Improving Vaccination Adherence in Inflammatory Bowel Diseases (Poster Presentation). Gastroenterology, 2019, 156, S-139-S-140.	0.6	0
132	P084 AN EVALUATION OF THE CLINICAL COURSE AND UTILIZATION PATTERNS FOR ACUTE AND CHRONIC POUCH-RELATED CONDITIONS AMONG PATIENTS TREATED IN A MULTICENTER COHORT. Gastroenterology, 2019, 156, S57-S58.	0.6	0
133	P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study. Journal of Crohn's and Colitis, 2019, 13, S312-S313.	0.6	0
134	1108 " Alkaline Phosphatase Levels Are Negatively Correlated With the Severity of Hepatic Steatosis in Patients With Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, S624-S625.	0.2	0
135	Reversing the Tide: Improving the Recruitment of Patients With Inflammatory Bowel Disease in Clinical Trials in the United States. Crohn's & Colitis 360, 2020, 2, .	0.5	0
136	Mo1887 IMPACT OF TUMOR NECROSIS FACTOR ALPHA ANTAGONISTS ON LIVER FAT AND BODY COMPOSITION MEASURED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH CROHN'S DISEASE. Gastroenterology, 2020, 158, S-963-S-964.	0.6	0
137	Mo1909 EVALUATION OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Gastroenterology, 2020, 158, S-973-S-974.	0.6	0
138	Su1858 SEVERITY OF HEPATIC STEATOSIS AND THIOPURINE USE INCREASE THE RISK OF DRUG INDUCED LIVER INJURY IN CROHN'S DISEASE. Gastroenterology, 2020, 158, S-677-S-678.	0.6	0
139	Sa1865 ASSOCIATION BETWEEN VEDOLIZUMAB LEVELS, ANTI-VEDOLIZUMAB LEVELS AND ENDOSCOPIC HEALING INDEX IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Gastroenterology, 2020, 158, S-456-S-457.	0.6	0
140	Su1918 CROHN'S DISEASE SMALL BOWEL STRICTURES: DEVELOPMENT AND RISK FOR SURGERY IN PATIENTS WITH SMALL BOWEL CROHN'S DISEASE. Gastroenterology, 2020, 158, S-702.	0.6	0
141	347 SERUM METABOLOMIC APPROACH IDENTIFIES SECONDARY BILE ACIDS GLYCOCHOLIC ACID AND GLYCOURSODEOXYCHOLIC ACID AS PREDICTIVE OF CROHN'S DISEASE CLINICAL RESPONSE TO VEDOLIZUMAB. Gastroenterology, 2020, 158, S-62.	0.6	0
142	A TRANSLATIONAL PHASE I STUDY OF TAUROURSODEOXYCHOLIC ACID (TUDCA) TO REDUCE SYMPTOMS AND ER STRESS IN ACTIVE ULCERATIVE COLITIS. Gastroenterology, 2021, 160, S8.	0.6	0
143	Medical and Endoscopic Management of Crohn Disease. Topics in Magnetic Resonance Imaging, 2021, 30, 43-61.	0.7	0
144	P584 Mucosal Eosinophilia is an Independent Predictor of Vedolizumab Effectiveness in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, S537-S537.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Sa511 INFLAMMATORY BOWEL DISEASES ARE ASSOCIATED WITH AN INCREASED RISK OF INCIDENT CARDIOVASCULAR DISEASE AND RELATED DEATH: A PROPENSITY MATCHED ANALYSIS OF THE UNITED KINGDOM BIOBANK STUDY. <i>Gastroenterology</i> , 2021, 160, S-529.	0.6	0
146	Sa542 INITIAL RESULTS FROM A MULTICENTER PROSPECTIVE REGISTRY EVALUATING POUCH-RELATED OUTCOMES. <i>Gastroenterology</i> , 2021, 160, S-542.	0.6	0
147	Sa486 PATIENTS WITH PENETRATING AND/OR STRICTURING CROHN'S DISEASE HAVE A HIGHER REPORTED PREVALENCE OF ACTIVE INTESTINAL AND EXTRA-INTESTINAL SYMPTOMS, SURGERIES AND NEED FOR BIOLOGICS: ANALYSIS OF THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT WITH IBD. <i>Gastroenterology</i> , 2021, 160, S-517-S-518.	0.6	0
148	Su605 QUANTIFICATION OF INTESTINAL PERMEABILITY IN HUMAN CROHN'S DISEASE: A PRELUDE TO SPECIMEN-FREE, NON-INVASIVE ASSESSMENT OF HUMAN GUT BARRIER INTEGRITY USING PYRAZINE DERIVED FLUOROPHORES. <i>Gastroenterology</i> , 2021, 160, S-753.	0.6	0
149	244 A SYSTEMATIC REVIEW OF THE DIAGNOSTIC CRITERIA, EFFICACY AND SAFETY OUTCOMES REPORTED IN STUDIES OF TREATMENT OF IMMUNE CHECKPOINT INHIBITOR COLITIS. <i>Gastroenterology</i> , 2021, 160, S-53.	0.6	0
150	A new way to assess the trajectory of remission in Crohn's disease: Correlating drug levels with a non-invasive blood-biomarker of mucosal remission. <i>Crohn's & Colitis</i> 360, 0, , .	0.5	0
151	S967 The Correlation Between Visceral Abdominal and Total Adipose Tissue With Metabolic Risk Factors in Patients With Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2021, 116, S463-S463.	0.2	0
152	S733 Novel Cytokine Signature Predicts Acute Intestinal Inflammation Identified on Magnetic Resonance Enterography in Crohn's Disease: A Role for IL-8, IL-10, IP-10, and MCP. <i>American Journal of Gastroenterology</i> , 2021, 116, S335-S336.	0.2	0
153	Tumor Necrosis Factor-Alpha Blockers do not Augment the Risk of Viral Infection in Inflammatory Bowel Disease (IBD): A Review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS). <i>American Journal of Gastroenterology</i> , 2012, 107, S636-S637.	0.2	0
154	Ischemic Colitis During Type I Interferon Therapy for Hepatitis C and Multiple Sclerosis. <i>American Journal of Gastroenterology</i> , 2012, 107, S210.	0.2	0
155	Disproportionate Lawyer Reporting of Inflammatory Bowel Disease Cases with Isotretinoin: A Review of the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). <i>American Journal of Gastroenterology</i> , 2012, 107, S638-S639.	0.2	0
156	Ischemic Colitis During Treatment with Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis. <i>American Journal of Gastroenterology</i> , 2012, 107, S208.	0.2	0
157	New-Onset Inflammatory Bowel Disease During Tumor Necrosis Factor-Alpha Inhibitor Therapy for Rheumatoid Arthritis and Juvenile Rheumatoid Arthritis: A Review of the Food and Drug Administration Adverse Event Reporting System and Literature. <i>American Journal of Gastroenterology</i> , 2012, 107, S621-S622.	0.2	0
158	Increased Risk of Osteoporosis Related Fractures in Patients with Irritable Bowel Syndrome: Presidential Poster. <i>American Journal of Gastroenterology</i> , 2012, 107, S702.	0.2	0
159	Concomitant Antibiotic Usage Does Not Further Increase the Risk of Inflammatory Bowel Disease with Isotretinoin Treatment for Acne: A Review of the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Gastroenterology</i> , 2012, 107, S645.	0.2	0
160	Preventing Patients with Crohn's Disease from Discontinuing Infliximab: A Dynamic Survival Model. <i>American Journal of Gastroenterology</i> , 2012, 107, S651.	0.2	0
161	Tumor Necrosis Factor-alpha Blocker Monotherapy or In Combination with Immunomodulators or Systemic Corticosteroids Does not Augment the Risk of Bacterial Infections: A Review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS). <i>American Journal of Gastroenterology</i> , 2012, 107, S650.	0.2	0
162	Safety of Polyethylene Glycol-based Preparations for Bowel Cleansing before Colonoscopy: An Analysis of the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Gastroenterology</i> , 2013, 108, S591.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Analysis of Drug-induced Liver Injury Reported with Tumor Necrosis Factor-alpha Inhibitors to the Food and Drug Administration Adverse Event Reporting System in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S513.	0.2	0
164	Marked Improvement in Severe and Refractory Formalin Colitis with Retinyl Palmitate Suppositories. American Journal of Gastroenterology, 2013, 108, S375-S376.	0.2	0
165	Analysis of the Food and Drug Administration Adverse Event Reporting System to Examine the Relationship between Tumor Necrosis Factor Alpha Inhibitor Therapy and Congestive Heart Failure among Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S520-S521.	0.2	0
166	Endoscopic Skipping of the Distal Terminal Ileum in Pediatric Crohn's Disease. American Journal of Gastroenterology, 2014, 109, S498.	0.2	0
167	Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease: ACG Fellows-In-Training Award. American Journal of Gastroenterology, 2015, 110, S786.	0.2	0
168	Utility and Safety of Balloon-Assisted Enteroscopy in Small Bowel Crohn's Disease: Single - Center Cohort Experience. American Journal of Gastroenterology, 2016, 111, S304.	0.2	0
169	Assessment of Gender and Racial Disparities in Quality of Care Indicators for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2017, 112, S604.	0.2	0
170	Inflammatory Bowel Diseases Dedicated Gastroenterologists Have Greater Adherence to Clinical Care Quality Indicators Than General Gastroenterologists. American Journal of Gastroenterology, 2017, 112, S349-S350.	0.2	0
171	Impact of a Standardized Reporting System for Magnetic Resonance Enterography on Small Bowel Crohn's Disease Management. American Journal of Gastroenterology, 2018, 113, S331.	0.2	0
172	Neither Obesity nor Hepatic Steatosis Are Associated With an Increased Prevalent or Incident Colonic Dysplasia in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, S402-S403.	0.2	0
173	P083 CREATION OF A PROSPECTIVE, LONGITUDINAL ADULT INFLAMMATORY BOWEL DISEASE COHORT COMBINING HIGH-RESOLUTION PHENOTYPING WITH BIOSAMPLE COLLECTION TO FACILITATE PRECISION MEDICINE: SPARC IBD. Gastroenterology, 2020, 158, S117.	0.6	0
174	Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1531-1532.	1.9	0